NCT00128921 · OUTCOME

Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2012-04-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Osteocalcin: Any Osteocalcin increase means positive response.

Cohort A: Received bortezomib 1.3 mg/m2 per days 1, 4, 8 and 11.

Cohort B: Received bortezomib 1.0 mg/m2 per days 1, 4, 8 and 11).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort A	10
Cohort B	6

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cohort A	4	Not reported	Not reported	Not reported	Not reported
Cohort B	3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Osteocalcin: Any Osteocalcin increase means positive response.

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

6 months

title

Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice